Craig Jones is an Assistant Professor of Computer Science at Johns Hopkins University's Whiting School of Engineering. He is affiliated with the Malone Center for Engineering in Healthcare and contributes to the Precision Medicine Analytics Platform's Imaging and Data Science Subcommittees. BSc in Computer Science and Mathematics from Simon Fraser University MSc in Medical Biophysics from the University of Western Ontario PhD in Physics from the University of British Columbia His research focuses on applying artificial intelligence and neural networks to medical image processing, particularly for MRI, CT, optical coherence tomography (OCT), and ultrasound datasets. Key areas include 2D/3D image processing, anomaly detection, segmentation, and uncertainty quantification, with clinical applications in neurosurgery, ophthalmology, and oncology. Projects span robotic imaging, neuroendoscopic guidance, and cancer boundary detection. Recent publications highlight advancements in vision-language models for 3D medical imaging, automated segmentation of venous malformations, and AI-guided neurosurgical tools. Articles emphasize multimodal data fusion, self-supervised learning, and federated learning for rare cancer analytics. He received a $310,000 Department of Defense grant in 2022 to develop AI-guided treatments for venous malformations. His work bridges clinical imaging domains and computer vision as a member of the Radiology AI Lab (RAIL), a collaborative effort across Johns Hopkins Hospital, the Whiting School of Engineering, and the Applied Physics Laboratory.
Nathaniel Nucci is an Associate Professor at Rowan University's College of Science & Mathematics, jointly appointed in the Department of Biological & Biomedical Sciences and Physics & Astronomy. His research bridges biophysics, structural biology, and nanotechnology to understand protein behavior in confined environments. Education Ph.D., Biochemistry and Molecular Biophysics, University of Pennsylvania M.S., Biochemistry and Molecular Biology, University of New Hampshire B.S., Biochemistry and Molecular Biology, University of New Hampshire Research Interests Dr. Nucci's lab focuses on: Protein biophysics in crowded/confining environments Reverse micelle technology for biomolecular studies Hydration dynamics of proteins (NMR-based methods) Structural biology of disease-related proteins (PHDs, p53) Drug delivery systems for protein therapeutics Nanoparticle synthesis with protein conjugation Research Trends His recent publications demonstrate expertise in using reverse micelles to study: Protein structural stability under confinement Hydration dynamics of therapeutic proteins Microenvironmental effects on phase-separating proteins Conformational changes in GPCRs Interfacial interactions in biomolecular systems Scientific Awards Gary J. Hunter Excellence in Mentoring Award (2024) College of Science and Mathematics Excellence in Academic Student Support (2022) Teaching Philosophy Emphasizes applied and experiential learning, integrating recent scientific discoveries into classroom practice and promoting hands-on scientific investigation.
James Lacefield is a Professor in both the Department of Electrical and Computer Engineering and the Department of Medical Biophysics at Western University. He serves as Director of the School of Biomedical Engineering and maintains his research laboratory in the Amit Chakma Engineering Building. His academic appointments span multiple disciplines, reflecting the interdisciplinary nature of his work in biomedical ultrasound imaging. Dr. Lacefield earned his Ph.D. and B.S.E. in Biomedical Engineering from Duke University. His educational background established the foundation for his current research program that bridges engineering principles with medical applications. His research focuses on the physical acoustics and signal processing aspects of ultrasound imaging, with particular emphasis on quantitative vascular imaging applications. Dr. Lacefield's laboratory develops novel methods for color Doppler, power Doppler, and contrast-enhanced ultrasound imaging, with primary applications in cancer research. Current projects include optimization of high-resolution ultrasound systems for tumor vascular characterization and development of methods to quantify spatial blood flow distribution in tumors. Analysis of his recent publications reveals a strong focus on quantitative ultrasound techniques for cancer applications, with particular attention to tumor perfusion assessment using contrast-enhanced ultrasound. His work demonstrates increasing sophistication in speckle analysis methods to improve the reliability of perfusion measurements in preclinical tumor models. Associate Editor, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control Member, Council of Chairs of Bioengineering and Biomedical Engineering Member, College of Reviewers, Canadian Institutes of Health Research Dr. Lacefield maintains active collaborations with multiple research groups including the Imaging Research Laboratories at Robarts Research Institute. His professional activities include editorial work for major ultrasound journals and participation in national review panels for biomedical research funding.
Michael Dustin is the Kennedy Trust Professor of Molecular Immunology and Director of Research at the Kennedy Institute of Rheumatology , University of Oxford. His career spans leadership roles at Washington University School of Medicine (1993–2000) and Skirball Institute of Biomolecular Medicine at NYU School of Medicine (2001–2013). Education : B.A. in Biology, Boston University (1984) Ph.D. in Cell and Developmental Biology, Harvard University (1990) Prof. Dustin's research focuses on the immunological synapse , a specialized interface between T cells and antigen-presenting cells. His work has revealed supramolecular attack particles as autonomous killing entities, synaptic ectosomes for TCR cargo transfer, and mechanistic insights into T cell signaling pathways. His recent publications highlight advancements in vaccine adjuvant response , T cell receptor dynamics , and glycosphingolipid synthesis in immune cells. Collaborations span neuroscience, cancer immunology, and rheumatology. Scientific Awards : Wellcome Trust Principal Research Fellowship European Research Council Advanced Grant (SYNECT) As Director of the NIH-funded Nanomedicine Center for Mechanobiology (2009–2014), he pioneered mechanobiology applications in immunology. Current projects integrate intravital microscopy and clinical translation for human diseases. His laboratory at Oxford investigates T cell regulation in autoimmune and inflammatory diseases, supported by an international network of collaborators including Wenbiao Gan, Dan Littman, and Dorian McGavern.
Fabio Zanini is an Associate Professor at the University of New South Wales (UNSW) , leading a research group focused on computational biology , single-cell approaches , and transcriptomic analysis across diseases like severe dengue , neonatal lung disease , cancer , and marine biology . He previously conducted postdoctoral research at Stanford University (2016-2019) and earned a PhD in Bioinformatics from the Max Planck Institute for Developmental Biology and the University of Tuebingen (2015). Current Affiliation: Group leader, UNSW Previous Training: Postdoc (Stanford), PhD (Max Planck/University of Tuebingen) His research spans single-cell RNA sequencing , computational virology , developmental cell biology , and bioinformatics tool development , with recent work on: Severe dengue progression (viral-host interactions, immune signatures) Lung development (endothelial cell diversity, hyperoxia-induced injury) Cancer genomics (mutant HSC clones, AZA therapy response) Marine biology (plankton transcriptomics, evolutionary analysis) Bioinformatics (HTSeq 2.0, northstar algorithm) Recent scientific awards include grants from the Chan Zuckerberg Initiative ($270,000), NIH R01 (multiple), ARC Discovery Grant , and NHMRC Ideas Grant . Notable contributions include: Northstar - Cell classification algorithm SpectralSeq - Hyperspectral-transcriptomic integration Tabula Muris - Mouse aging atlas He has supervised research into hematopoietic stem cell regulation , lung vascular development , and autophagy in viral infections , with collaborations across Stanford , University of Sydney , and Harvard .
Dr. Emre Sefer is an Associate Professor at the Faculty of Engineering, Özyeğin University, specializing in machine learning and bioinformatics. He holds a Ph.D. in Computational Biology from Carnegie Mellon University (2015), an M.S. in Computer Science from University of Maryland College Park (2011), and a B.S. in Computer Engineering from Boğaziçi University (2008). His research bridges graph machine learning with financial networks, bioinformatics, and data engineering. Ph.D.: Computational Biology, Carnegie Mellon University M.S.: Computer Science, University of Maryland College Park B.S.: Computer Engineering, Boğaziçi University Research focuses on applying machine learning to financial and biological networks: Bioinformatics : 3D genome modeling, protein modifications, transcriptomic analysis Graph Machine Learning : GNNs for fraud detection, drug response prediction, and network evolution Financial Networks : Cryptocurrency investment strategies, asset price prediction His lab (OzU Machine Learning in Finance and Bioinformatics Lab) develops graph-based deep learning methods for cross-domain applications, including NFT market analysis and chromatin structure prediction. He received the Best research paper award at Recomb 2016 for work on 3D genome architecture. Former postdoc at CMU Machine Learning Department Industry experience as Quantitative Strategist at Goldman Sachs and JPMorgan
Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis
Professor Udo Oppermann serves as Professor of Molecular Biology and Director of Laboratory Sciences at the Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford. He is also Deputy Director of the Oxford Centre of Translational Myeloma Research and a fellow at St Catherine's College. His educational background includes a Diploma in Human Biology (1990) and PhD in Pharmacology and Toxicology (1994), both earned with distinctions from Philipps University Marburg. Prior academic appointments include Associate Professor at Karolinska Institutet (until 2004) and sabbatical work at Yale University. Research focuses on epigenetic mechanisms in disease through drug and target discovery using systems biology and single-cell approaches . Key disease targets include metabolic disorders, inflammatory conditions, and malignant diseases—particularly multiple myeloma and secondary bone cancers. His group pioneers chemical biology applications in primary tumor microenvironments. Current funding sources include Cancer Research UK, Innovate UK, EPSRC, Royal Society-Newton Fund, Bristol Myers Squibb, Bayer Healthcare, GlaxoSmithKline, Blood Cancer UK, and Leducq Foundation. Notable research trends show increasing emphasis on epigenetic regulation in immune cells (2020-2024), single-cell technologies for myeloma (2022-2024), and translational applications of chromatin modifiers (2016-2019). Recent work integrates metabolomics with epigenetic mechanisms in gynecological and hematological disorders. He supervises doctoral research including Singh K.'s 2024 thesis on sonodynamic therapy mechanisms. Leadership roles encompass directing Oxford's Molecular Laboratory Sciences division and co-leading translational myeloma research initiatives.
Olga G. Troyanskaya is a Professor of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She serves as Deputy Director for Genomics at the Simons Center for Data Analysis, Simons Foundation, NYC. Her research focuses on computational biology, integrating diverse high-throughput genomic datasets to model molecular pathways in health and disease. Professor of Computer Science and Lewis-Sigler Institute for Integrative Genomics Deputy Director for Genomics, Simons Center for Data Analysis Research Interests: Troyanskaya’s work addresses challenges in bioinformatics, including algorithm development for gene expression analysis, regulatory network modeling, and disease mechanism interpretation. She combines computational methods with experimental validation using S. cerevisiae as a model organism. Scientific Trends: Recent publications emphasize single-cell multiomics, deep learning for transcriptional regulation, cancer immunotherapy design, and epigenomic analysis of immune responses. Key themes include computational modeling of genetic networks, disease-specific pathway analysis, and high-resolution omics frameworks. Collaborative roles in autism, Alzheimer’s, kidney disease, and cancer research Developed tools like HumanBase for data-driven predictions
Lion Shahab is a Professor of Health Psychology at University College London (UCL) , where he leads the Research Department of Behavioural Science and Health . His work focuses on smoking cessation , e-cigarette impact , tobacco control policy , and behavioral science in public health. Education: MA in Psychology, Philosophy, and Physiology (University of Oxford, 2003) MSc in Health Psychology (King’s College London, 2004) PhD in Health Psychology (University of London, 2008) MSc in Neuroscience (UCL, 2010) Stage II Health Psychology Qualification (UCL, 2012) Research Interests include biomarker feedback for behavior change, nicotine product regulation, smoking-related diseases, novel cessation interventions, and the interplay between nicotine use and mental health. His methods span human trials, epidemiology, and animal electrophysiology studies. Articles Trends highlight his focus on vaping epidemiology , smoking cessation pharmacology , and public health policy modeling . Recent work addresses the long-term impact of e-cigarettes, secondhand exposure risks, and regulatory strategies. Scientific Awards : Fellow of the Society for Research on Nicotine and Tobacco (2023) Fellow of the British Psychological Society (2023) Seelye Visiting Fellow at the University of Auckland (2024) He supervises MSc and PhD students and co-directs the UCL Tobacco and Alcohol Research Group . His editorial roles include Deputy Editor at Nicotine & Tobacco Research and Senior Editor at Addiction .
Hans H. Wandall is Professor and Deputy Head of Department at the University of Copenhagen's Department of Cellular and Molecular Medicine, Faculty of Health Sciences. He serves as Group Leader and Vice-Director of the Copenhagen Center for Glycomics. His educational background includes a PhD in Glycobiology (2004), medical licensure (2001), and MD from University of Copenhagen (1999). Research focuses on glycobiology using gene editing and tissue models to understand glycan functions in: Tissue development and cancer biology Host-virus interactions (HSV-1, Ebola) Stem cell regulation and regenerative medicine Glycan-based therapeutic development Recent publications demonstrate interdisciplinary approaches combining glycoproteomics, virology, and cancer biology, with emphasis on O-glycosylation mechanisms and viral pathogenesis. Awards & Recognition: ERC Consolidator Grant (2017) Lundbeck Foundation Ascending Investigator (2019) Sapere Aude Research Leader Award (2012) Young Scientist Award (2003) Leads multiple funded projects from Lundbeck Foundation, Novo Nordisk Foundation, and Danish National Research Foundation. Supervises doctoral candidates and postdoctoral researchers while directing the GlycoMedicine research group. Founded biotech ventures including GO-Therapeutics and Hemab ApS.
Prof. Kwang W. Oh is a tenured Professor at the Department of Electrical Engineering and Department of Biomedical Engineering within the School of Engineering and Applied Sciences at University at Buffalo (SUNY at Buffalo) . He serves as the Director of Graduate Studies in Electrical Engineering and Director of SMALL (Sensors and MicroActuators Learning Lab) . His academic journey includes PhD and MS in Electrical and Computer Engineering from University of Cincinnati (2001, 1997) and BS in Physics from Chonbuk National University (1995). Prof. Oh's research expertise lies at the intersection of microfluidics , BioMEMS , and lab-on-a-chip technologies. His lab has pioneered vacuum-driven microfluidic devices , PDMS-based systems , droplet manipulation , and chemical-free fabrication techniques . His work enables point-of-care diagnostics , single cell analysis , and wearable medical sensors , with significant contributions to sample-to-answer nanosystems and world-to-chip interfacing . The scientific awards section highlights his excellence in teaching and research: SUNY Chancellor's Award for Excellence in Teaching (2020) Meyerson Award for Undergraduate Teaching (2019) Qualcomm Faculty Award (2019) Senior Teacher of the Year (2017) Royal Society of Chemistry's Emerging Investigators (2013) Samsung Electronics' CEO Honor (2003) His lab has produced numerous PhD and MS students including Dr. Anyang Wang (2020), Dr. Nikhila Nyayapathi (2020), Mr. Liam Christie (2021), and Dr. Domin Koh (2019). As a conference chair , he has organized symposia at NanoTech (2012-2026) and served as editorial board member for Sensors , Micromachines , and Biomedical Engineering Letters .
David J. Brenner serves as Higgins Professor of Radiation Biophysics in Radiation Oncology and Environmental Health Sciences at Columbia University Medical Center. He directs both the century-old Center for Radiological Research and the Radiological Research Accelerator Facility (RARAF), leading interdisciplinary teams focused on radiation applications in medicine and safety. BA in Physics from Oxford University (1974) MSc in Radiation Physics from University of London (1976) MA in Physics Philosophy from Oxford University (1979) PhD in Physics from University of Surrey (1980) His research spans dual aspects of radiation: therapeutic applications in cancer treatment and risk assessment across diverse scenarios. Key initiatives include advancing carbon-ion therapy for pancreatic cancer, developing safe far-UVC light for pathogen elimination, and investigating low-dose radiation risks from medical imaging to nuclear terrorism. His team leverages RARAF's unique capabilities for mechanistic studies of radiation effects. Publications reveal dominant themes in radiation biophysics, with significant contributions to biodosimetry (RABiT platform), UV disinfection technology, and cancer risk modeling. Recent work emphasizes translational applications including medical countermeasures for radiation exposure and precision radiation oncology techniques. National Academy of Sciences Nuclear and Radiation Studies Board member National Council on Radiation Protection and Measurements member Radiation Research Society Failla Gold Medal recipient (2011) Oxford University Weldon Prize for mathematical biology (2015) Robert D. Moseley Award for Radiation Protection in Medicine Brenner leads multiple NIH-funded projects including biodosimetry development and UV disinfection research. His mentorship extends through directing Columbia's Radiological Research Accelerator Facility and training programs in radiological sciences. Current lab efforts focus on carbon-ion therapy mechanisms and 222-nm UV applications against drug-resistant pathogens, with active collaborations across oncology, microbiology, and physics disciplines.
E. Jennifer Edelman, MD, MHS is a Professor of Medicine (General Internal Medicine) at Yale School of Medicine and an Associate Professor on Term in Social and Behavioral Sciences at Yale School of Public Health. She serves as an HIV provider at the Yale-New Haven Hospital Nathan Smith HIV Clinic and is the physician consultant in the Addiction Medicine Treatment Program. Dr. Edelman is certified as an internist, HIV specialist, and in Addiction Medicine, and holds multiple appointments across Yale's medical and public health institutions. Professor of Medicine, General Internal Medicine (Primary) Associate Professor on Term, Social and Behavioral Sciences (Secondary) Addiction Medicine Fellowship Program AIDS Care Program Internal Medicine Program in Addiction Medicine Yale Center for Clinical Investigation (co-Director of Education) Yale-Drug use, Addiction, and HIV prevention Research Scholars (DAHRS) Dr. Edelman's research focuses on optimizing HIV prevention and treatment in the context of substance use, including opioid, alcohol, and tobacco use. Applying a range of methodologies, she leads and collaborates on NIH-funded projects to evaluate novel and implement evidence-based addiction treatment in medical settings, especially HIV treatment settings. Her work has focused on understanding harms associated with opioid use among people with HIV and promoting HIV prevention, including use of pre-exposure prophylaxis (PrEP). She collaborates extensively with community-based and public health partners to advance these goals. Analysis of her recent publications (2024-2025) reveals a strong emphasis on integrated care models addressing substance use disorders within HIV treatment settings. Her research spans multiple methodologies including randomized controlled trials, implementation science, qualitative studies, and epidemiological analyses. Key themes include contingency management for alcohol use disorder among people with HIV, PrEP implementation among high-risk populations, and interventions for tobacco cessation in HIV clinics. Her work demonstrates a consistent focus on addressing health disparities and improving outcomes for vulnerable populations. Dr. Robert A. Savitt & Dr. George D. McCormack Award (2022) Lipkin Award Finalist, Society of General Internal Medicine National Annual Meeting (2021) Lipkin Award Finalist, Society of General Internal Medicine National Annual Meeting (2019) Veterans Affairs Locally-Initiated Project Funding Award New England Society of General Internal Medicine Award for Excellence in Clinical Investigation Society of General Internal Medicine Lawrence Linn Award Dr. Edelman actively mentors trainees including post-doctoral fellows and public health students, and serves as Associate Director of the Research on Addiction Medicine Scholars (RAMS) Program. She regularly serves on NIH grant review committees and is Associate Editor of Addiction Science and Clinical Practice. Her current research includes the EXHIT ENTRE trial (Exemplar Hospital Initiation Trial to Enhance Treatment Engagement), which focuses on addressing untreated alcohol use disorder in hospital settings. She has received substantial grant funding from the National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, and National Cancer Institute to support her work in addiction medicine and HIV care.
Alessandra Luchini serves as Professor in George Mason University's School of Systems Biology and the Center for Applied Proteomics and Molecular Medicine (CAPMM), where she pioneers nanotechnology solutions for cancer and infectious disease diagnostics. Her work bridges biomolecular interface engineering with clinical translation through advanced proteomic platforms. Education Ph.D. from University of Padova, Italy Research Focus : Dr. Luchini's program centers on nanoproteomics for biomarker discovery, specifically developing hydrogel-based affinity capture systems to detect urinary biomarkers of Lyme disease, Chagas disease, and tuberculosis. Her lab innovates in biomimetic membrane models using neutron reflectometry to study pathogen-host interactions, while translating findings into point-of-care diagnostic devices through CAPMM's clinical partnerships. Publication Trends : Recent work (2024-2025) reveals three converging trajectories: (1) urinary peptide diagnostics for tick-borne illnesses validated against clinical symptom scores, (2) engineered nanoparticle networks for pathogen sequestration in blood/plasma, and (3) membrane biophysics studies enabling targeted drug delivery. This integration of basic membrane science with clinical proteomics defines her translational approach. Awards 2023 SCHEV Outstanding Faculty Award for Virginia higher education Research Leadership : As CAPMM principal investigator, Dr. Luchini directs NIH-funded projects developing FDA-cleared diagnostic platforms. Her team collaborates with CDC on Babesia diagnostics and with oncology centers on field cancerization proteomics, while mentoring postdocs in nanoparticle engineering and mass spectrometry techniques. Infrastructure : The CAPMM core facility houses state-of-the-art mass spectrometers, neutron reflectometers, and GMP-compliant nanoparticle synthesis equipment, supporting her lab's work on urinary biomarker validation and affinity capture technology development.
